Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + daunorubicin + midostaurin
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy used for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients with FLT3 mutations. The regimen consists of two chemotherapy agents—cytarabine and daunorubicin—combined with the targeted agent midostaurin. Cytarabine and daunorubicin are traditional chemotherapeutic drugs that destroy rapidly dividing cells, including cancer cells. Midostaurin is a small molecule tyrosine kinase inhibitor that blocks several kinases, most notably FLT3, which is frequently mutated in AML. By inhibiting FLT3 and other kinases such as c-KIT and PDGFR, midostaurin disrupts signaling pathways essential for leukemia cell proliferation and survival[1][2][6]. This combination has been shown to improve outcomes in patients with FLT3-mutated AML when used during induction (initial) and consolidation phases of chemotherapy[1][2][5].
- Brand names
- Rydapt (for midostaurin)cerubidine (for daunorubicin)Cytosar (for cytarabine)
- Other names
- cytarabine + daunorubicin + midostaurin7+3 regimen plus midostaurin
02
Targets
PDGFR (PDGFR family)DNA polymerase familyTOP2A (DNA topoisomerase II)KIT (c-KIT proto-oncogene receptor tyrosine kinase)SFK (SRC family kinases)DNASYK (Spleen Tyrosine Kinase)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR (VEGFR family)
Beyond the preview
Go deeper on cytarabine + daunorubicin + midostaurin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + daunorubicin + midostaurin.